New drug combo shows promise for Hard-to-Treat breast cancer

This study is testing a combination of two drugs, utidelone and bevacizumab, in people with advanced HER-2 negative breast cancer who have already tried at least two other treatments. The goal is to see if this combination can slow down the cancer's growth and improve outcomes. About 79 participants will be enrolled, and the study will measure how long they live without the cancer getting worse.